Morton G - Search Results

1

Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?

Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E, Flavin A. Choo R, et al. Among authors: morton g. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):674-80. doi: 10.1016/s0360-3016(01)02677-3. Int J Radiat Oncol Biol Phys. 2002. PMID: 11849789

2

Target position variability throughout prostate radiotherapy.

Dawson LA, Mah K, Franssen E, Morton G. Dawson LA, et al. Among authors: morton g. Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1155-61. doi: 10.1016/s0360-3016(98)00265-x. Int J Radiat Oncol Biol Phys. 1998. PMID: 9869243

3

Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.

Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Nam RK, et al. Among authors: morton g. J Urol. 1999 May;161(5):1521-4. J Urol. 1999. PMID: 10210387

4

Early prostate cancer.

Morton GC. Morton GC. Curr Probl Cancer. 2000 Jan-Feb;24(1):5-51. doi: 10.1016/s0147-0272(00)90007-2. Curr Probl Cancer. 2000. PMID: 10749454 Review. No abstract available.

5

Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist's view.

Choo CR, Danjoux C, Morton GC. Choo CR, et al. Among authors: morton gc. Can J Urol. 2000 Jun;7(3):1043-50. Can J Urol. 2000. PMID: 11118280 Review.

6

Pathological T3 and/or margin positive prostate adenocarcinoma with undetectable postoperative PSA - to irradiate or not?: analysis of freedom from PSA failure.

Flavin A, Choo R, Franssen E, Danjoux C, Morton G. Flavin A, et al. Among authors: morton g. Can J Urol. 1998 Jun;5(2):544-550. Can J Urol. 1998. PMID: 11299112

7

The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer.

Hruby G, Choo R, Klotz L, Danjoux C, Murphy J, Deboer G, Morton G, Rakovitch E, Szumacher E, Fleshner N. Hruby G, et al. Among authors: morton g. BJU Int. 2001 May;87(7):643-7. doi: 10.1046/j.1464-410x.2001.02133.x. BJU Int. 2001. PMID: 11350404

8

PSA doubling time of prostate carcinoma managed with watchful observation alone.

Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. Choo R, et al. Among authors: morton gc. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):615-20. doi: 10.1016/s0360-3016(01)01511-5. Int J Radiat Oncol Biol Phys. 2001. PMID: 11395227 Clinical Trial.

9

Controversies in prostate cancer radiotherapy: consensus development.

Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L; Canadian GU Radiation Oncologist Group. Lukka H, et al. Among authors: morton g. Can J Urol. 2001 Aug;8(4):1314-22. Can J Urol. 2001. PMID: 11564274 Review.

10

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Choo R, et al. Among authors: morton gc. J Urol. 2002 Apr;167(4):1664-9. J Urol. 2002. PMID: 11912384

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

569 results

Search Page

Filters